JUN 23, 2020 3:24 PM PDT

Psychedelic DMT to Enter Clinical Trials

WRITTEN BY: Annie Lennon

Neuro-pharmaceutical company, MindMed, has announced that it will begin a double-blind placebo-controlled Phase 1 clinical trial to understand how N, N-Dimethyltryptamine (DMT), the primary psychoactive ingredient in Ayahuasca, works in the body. The company ultimately hopes to create therapeutics with the substance to treat mental health conditions like depression and addiction. 

“There is a growing trend in Western society to use Ayahuasca and DMT to facilitate a healing process for one’s mind. However, there is very limited safety data and clinical trials evaluating DMT as a potential medicine so we are going to double down on understanding the therapeutic opportunity and more effective ways to administer DMT in a controlled setting to achieve this healing process.” says JR Rahn, cofounder of MindMed. 

There are currently no approved clinical uses for DMT. The substance has nevertheless been used for centuries, if not longer, by various civilizations and tribes around the world for both its mentally restorative and explorative effects. In the first clinical trial of its kind, the researchers want to establish whether the substance could be engineered for future drug development programs to treat conditions like addiction. 

In partnership with the University Hospital Basel’s Liechti Lab, the researchers from MindMed thus plan to conduct experiments in which patients receive DMT intravenously. Quickly metabolized if taken orally, taking DMT intravenously means that the researchers will both be able to ensure continuous application of the substance, and thus a prolonged DMT experience.

It also means they will be able to stop administration of the substance and the ensuing DMT experience quickly should anything go wrong. In this way, the researchers hope to establish proper dosing during the trial with the goal of inducing a stable DMT experience of between an hour and two hours among patients. 

The study is expected to begin in late 2020, from which the researchers hope to lay the foundations for a future Phase II clinical proof of concept trials. 

 

Sources: MindMed, Bezinga

 

About the Author
University College London
Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
FEB 22, 2022
Cancer
What's Killing My Cell Cultures? Troubleshooting Cell Growth Issues
FEB 22, 2022
What's Killing My Cell Cultures? Troubleshooting Cell Growth Issues
Nothing's more maddening than cells that won't grow or cell cultures that won't attach. Stunted cell growth and erratic ...
MAR 03, 2022
Drug Discovery & Development
Blood Pressure Drug Increases Natural Insulin Production in Type 1 Diabetes
MAR 03, 2022
Blood Pressure Drug Increases Natural Insulin Production in Type 1 Diabetes
Individuals with type 1 diabetes who take blood pressure medication verapamil require less insulin on a daily basis. The ...
MAR 22, 2022
Drug Discovery & Development
Medical Marijuana May Be Overhyped for Pain, Anxiety, Depression
MAR 22, 2022
Medical Marijuana May Be Overhyped for Pain, Anxiety, Depression
Claims about medical marijuana treating multiple mental health and neurological disorders may be overhyped, according to ...
MAR 23, 2022
Immunology
Drug That Reverses Immune Aging Can Prevent COVID-19 Death
MAR 23, 2022
Drug That Reverses Immune Aging Can Prevent COVID-19 Death
As we age, parts of our bodies get old and worn out, including the immune system. That's one reason why COVID-19 has bee ...
APR 05, 2022
Drug Discovery & Development
Alzheimer's Drug May improve Symptoms of Down Syndrome
APR 05, 2022
Alzheimer's Drug May improve Symptoms of Down Syndrome
A protein named GM-CSF used to treat Alzheimer's disease improves cognitive function in mice with Down syndrome (DS) ...
APR 15, 2022
Drug Discovery & Development
Low-dose Lithium Has Anti-aging Effects on Liver
APR 15, 2022
Low-dose Lithium Has Anti-aging Effects on Liver
Low-dose lithium can block an enzyme linked to cellular aging and functional decline in the kidneys. The corresponding s ...
Loading Comments...